|
|
| Line 1: |
Line 1: |
| {{#widget:SchemaSnippet}} | | {{#widget:SchemaSnippet}} |
| == Recommendations for Utility of the Liver Biopsy and Noninvasive Tests of Fibrosis: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
| |
| {{cquote|
| |
| '''1.''' A liver biopsy should be considered in patients with chronic hepatitis C infection if the patient and health care provider wish information regarding fibrosis stage for prognostic purposes or to make a decision regarding treatment ''(Class IIa, Level B)''
| |
|
| |
| '''2.''' Currently available noninvasive tests may be useful in defining the presence or absence of advanced fibrosis in persons with chronic hepatitis C infection, but should not replace the liver biopsy in routine clinical practice (''Class IIb, Level C)''.}}
| |
|
| |
| ==References== | | ==References== |
| {{Reflist|2}} | | {{Reflist|2}} |